Secretion of GIP in responders to acarbose in obese Type 2(NIDDM) patients

Izumi Takei, Kazunori Miyamoto, Osamu Funae, Norimi Ohashi, Shu Meguro, Mikiya Tokui, Takao Saruta

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Acarbose has been shown to reduce postprandial hyperglycemia and to improve lipid parameters in diabetics via its inhibitory effects on intestinal α-glucosidases. Response to acarbose may therefore be dependent upon gastric or pancreatic hormone function. To test this hypothesis, we treated 27 mild type 2 (NIDDM) Japanese diabetics who were mildly obese with low-dose acarbose (150 mg/day) for 3 months. We then performed a responder analysis to determine specific hormonal responses that may be associated with a good response to acarbose. At the end of the treatment period, a total of 15 evaluable patients was grouped as responders (n=6) and nonresponders (n=9) based on an effective decrease in postprandial glucose levels (>30 mg/day) and glycosylated hemoglobin (HbA1c) levels (>0.5%). There were no differences between the two groups in demographic variables or mean postprandial glucose levels at baseline. There was a small but significant increase in postprandial cholecystokinin (CCK) in responders, and fasting gastric inhibitory peptide (GIP) levels were significantly increased in responders and all patients after treatment. Serum leptin levels were reduced by treatment in our mildly obese responders and this was associated with a significant decrease in body weight. These results suggest that treatment with low-dose acarbose may reduce hyperglycemia in mild type 2 Japanese patients and may improve metabolic control by regulating hormones involved in glycemic control and digestive absorption. Acarbose may provide a safe adjunct to help treat insulin resistance in type 2 patients.

Original languageEnglish
Pages (from-to)245-249
Number of pages5
JournalJournal of Diabetes and its Complications
Volume15
Issue number5
DOIs
Publication statusPublished - 2001

Fingerprint

Acarbose
Type 2 Diabetes Mellitus
Stomach
Peptides
Hyperglycemia
Pancreatic Hormones
Glucosidases
Glucose
Cholecystokinin
Glycosylated Hemoglobin A
Therapeutics
Leptin
Insulin Resistance
Fasting
Body Weight
Demography
Hormones
Lipids
Serum

Keywords

  • Acarbose
  • GIP
  • Leptin
  • Obesity
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Secretion of GIP in responders to acarbose in obese Type 2(NIDDM) patients. / Takei, Izumi; Miyamoto, Kazunori; Funae, Osamu; Ohashi, Norimi; Meguro, Shu; Tokui, Mikiya; Saruta, Takao.

In: Journal of Diabetes and its Complications, Vol. 15, No. 5, 2001, p. 245-249.

Research output: Contribution to journalArticle

Takei, Izumi ; Miyamoto, Kazunori ; Funae, Osamu ; Ohashi, Norimi ; Meguro, Shu ; Tokui, Mikiya ; Saruta, Takao. / Secretion of GIP in responders to acarbose in obese Type 2(NIDDM) patients. In: Journal of Diabetes and its Complications. 2001 ; Vol. 15, No. 5. pp. 245-249.
@article{aac424ec92bf4077abd0364330156e15,
title = "Secretion of GIP in responders to acarbose in obese Type 2(NIDDM) patients",
abstract = "Acarbose has been shown to reduce postprandial hyperglycemia and to improve lipid parameters in diabetics via its inhibitory effects on intestinal α-glucosidases. Response to acarbose may therefore be dependent upon gastric or pancreatic hormone function. To test this hypothesis, we treated 27 mild type 2 (NIDDM) Japanese diabetics who were mildly obese with low-dose acarbose (150 mg/day) for 3 months. We then performed a responder analysis to determine specific hormonal responses that may be associated with a good response to acarbose. At the end of the treatment period, a total of 15 evaluable patients was grouped as responders (n=6) and nonresponders (n=9) based on an effective decrease in postprandial glucose levels (>30 mg/day) and glycosylated hemoglobin (HbA1c) levels (>0.5{\%}). There were no differences between the two groups in demographic variables or mean postprandial glucose levels at baseline. There was a small but significant increase in postprandial cholecystokinin (CCK) in responders, and fasting gastric inhibitory peptide (GIP) levels were significantly increased in responders and all patients after treatment. Serum leptin levels were reduced by treatment in our mildly obese responders and this was associated with a significant decrease in body weight. These results suggest that treatment with low-dose acarbose may reduce hyperglycemia in mild type 2 Japanese patients and may improve metabolic control by regulating hormones involved in glycemic control and digestive absorption. Acarbose may provide a safe adjunct to help treat insulin resistance in type 2 patients.",
keywords = "Acarbose, GIP, Leptin, Obesity, Type 2 diabetes",
author = "Izumi Takei and Kazunori Miyamoto and Osamu Funae and Norimi Ohashi and Shu Meguro and Mikiya Tokui and Takao Saruta",
year = "2001",
doi = "10.1016/S1056-8727(01)00148-9",
language = "English",
volume = "15",
pages = "245--249",
journal = "Journal of Diabetes and its Complications",
issn = "1056-8727",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Secretion of GIP in responders to acarbose in obese Type 2(NIDDM) patients

AU - Takei, Izumi

AU - Miyamoto, Kazunori

AU - Funae, Osamu

AU - Ohashi, Norimi

AU - Meguro, Shu

AU - Tokui, Mikiya

AU - Saruta, Takao

PY - 2001

Y1 - 2001

N2 - Acarbose has been shown to reduce postprandial hyperglycemia and to improve lipid parameters in diabetics via its inhibitory effects on intestinal α-glucosidases. Response to acarbose may therefore be dependent upon gastric or pancreatic hormone function. To test this hypothesis, we treated 27 mild type 2 (NIDDM) Japanese diabetics who were mildly obese with low-dose acarbose (150 mg/day) for 3 months. We then performed a responder analysis to determine specific hormonal responses that may be associated with a good response to acarbose. At the end of the treatment period, a total of 15 evaluable patients was grouped as responders (n=6) and nonresponders (n=9) based on an effective decrease in postprandial glucose levels (>30 mg/day) and glycosylated hemoglobin (HbA1c) levels (>0.5%). There were no differences between the two groups in demographic variables or mean postprandial glucose levels at baseline. There was a small but significant increase in postprandial cholecystokinin (CCK) in responders, and fasting gastric inhibitory peptide (GIP) levels were significantly increased in responders and all patients after treatment. Serum leptin levels were reduced by treatment in our mildly obese responders and this was associated with a significant decrease in body weight. These results suggest that treatment with low-dose acarbose may reduce hyperglycemia in mild type 2 Japanese patients and may improve metabolic control by regulating hormones involved in glycemic control and digestive absorption. Acarbose may provide a safe adjunct to help treat insulin resistance in type 2 patients.

AB - Acarbose has been shown to reduce postprandial hyperglycemia and to improve lipid parameters in diabetics via its inhibitory effects on intestinal α-glucosidases. Response to acarbose may therefore be dependent upon gastric or pancreatic hormone function. To test this hypothesis, we treated 27 mild type 2 (NIDDM) Japanese diabetics who were mildly obese with low-dose acarbose (150 mg/day) for 3 months. We then performed a responder analysis to determine specific hormonal responses that may be associated with a good response to acarbose. At the end of the treatment period, a total of 15 evaluable patients was grouped as responders (n=6) and nonresponders (n=9) based on an effective decrease in postprandial glucose levels (>30 mg/day) and glycosylated hemoglobin (HbA1c) levels (>0.5%). There were no differences between the two groups in demographic variables or mean postprandial glucose levels at baseline. There was a small but significant increase in postprandial cholecystokinin (CCK) in responders, and fasting gastric inhibitory peptide (GIP) levels were significantly increased in responders and all patients after treatment. Serum leptin levels were reduced by treatment in our mildly obese responders and this was associated with a significant decrease in body weight. These results suggest that treatment with low-dose acarbose may reduce hyperglycemia in mild type 2 Japanese patients and may improve metabolic control by regulating hormones involved in glycemic control and digestive absorption. Acarbose may provide a safe adjunct to help treat insulin resistance in type 2 patients.

KW - Acarbose

KW - GIP

KW - Leptin

KW - Obesity

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=0034868915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034868915&partnerID=8YFLogxK

U2 - 10.1016/S1056-8727(01)00148-9

DO - 10.1016/S1056-8727(01)00148-9

M3 - Article

C2 - 11522498

AN - SCOPUS:0034868915

VL - 15

SP - 245

EP - 249

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

IS - 5

ER -